119-hr1561

HR
✓ Complete Data

ALERT Communities Act

Login to track bills
Introduced:
Feb 25, 2025
Policy Area:
Health

Bill Statistics

3
Actions
1
Cosponsors
1
Summaries
8
Subjects
1
Text Versions
Yes
Full Text

AI Summary

No AI Summary Available

Click the button above to generate an AI-powered summary of this bill using Claude.

The summary will analyze the bill's key provisions, impact, and implementation details.

Latest Action

Feb 25, 2025
Referred to the House Committee on Energy and Commerce.

Summaries (1)

Introduced in House - Feb 25, 2025 00
<p><strong>Advancing Lifesaving Efforts with Rapid Test strips for Communities Act or the ALERT Communities Act</strong></p><p>This bill establishes programs and requirements to advance the development and usage of test strips that detect the presence of certain hazardous drugs (e.g.,&nbsp;fentanyl, xylazine). </p><p>Currently, the Substance Abuse and Mental Health Services Administration provides grants to government entities to train and provide authorized equipment to first responders and other relevant personnel for emergency treatment of opioid overdoses. The bill expands these grants to include rapid response test strips for detecting the presence of fentanyl, xylazine, and other synthetic opioids or emerging substances in people or within other drugs.</p><p>Additionally, the bill requires the Department of Health and Human Services (HHS) to publish guidance and standards for test strip manufacturers to support the development, evaluation, and authorization of test strips.</p><p>Also, HHS must conduct a study and report to Congress on how the availability and usage of test strips and similar equipment impacts the frequency of overdoses and participation in substance use disorder treatment.&nbsp;</p>

Actions (3)

Referred to the House Committee on Energy and Commerce.
Type: IntroReferral | Source: House floor actions | Code: H11100
Feb 25, 2025
Introduced in House
Type: IntroReferral | Source: Library of Congress | Code: Intro-H
Feb 25, 2025
Introduced in House
Type: IntroReferral | Source: Library of Congress | Code: 1000
Feb 25, 2025

Subjects (8)

Congressional oversight Drug trafficking and controlled substances First responders and emergency personnel Government studies and investigations Health (Policy Area) Medical research Medical tests and diagnostic methods Research administration and funding

Cosponsors (1)

(R-TX)
Feb 25, 2025

Text Versions (1)

Introduced in House

Feb 25, 2025

Full Bill Text

Length: 3,624 characters Version: Introduced in House Version Date: Feb 25, 2025 Last Updated: Nov 13, 2025 6:35 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1561 Introduced in House

(IH) ]

<DOC>

119th CONGRESS
1st Session
H. R. 1561

To require research with respect to fentanyl and xylazine test strips,
to authorize the use of grant funds for such test strips, and for other
purposes.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

February 25, 2025

Ms. Crockett (for herself and Mr. Gooden) introduced the following
bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

A BILL

To require research with respect to fentanyl and xylazine test strips,
to authorize the use of grant funds for such test strips, and for other
purposes.

Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1.

This Act may be cited as the ``Advancing Lifesaving Efforts with
Rapid Test strips for Communities Act'' or the ``ALERT Communities
Act''.
SEC. 2.
Section 546 (c) of the Public Health Service Act (42 U.
(c) of the Public Health Service Act (42 U.S.C. 290ee-
1
(c) ) is amended--

(1) in paragraph

(3) , by striking ``; and'' and inserting a
semicolon;

(2) in paragraph

(4) , by striking the period and inserting
``; and''; and

(3) by adding at the end the following:
``

(5) train and provide resources for first responders and
members of other relevant community sectors on carrying and
facilitating access to fentanyl or xylazine test strips (as
defined in
section 5 of the Advancing Lifesaving Efforts with Rapid Test strips for Communities Act).
Rapid Test strips for Communities Act).''.
SEC. 3.

The Secretary of Health and Human Services, in consultation with
the Director of the National Institutes of Health, the Director of the
Office of National Drug Control Policy, the Commissioner of Food and
Drugs, and the Administrator of the Drug Enforcement Administration,
shall develop and make publicly available research and marketing
frameworks for developing, improving, and evaluating test strip
technology for detecting fentanyl and other dangerous substances. Such
frameworks shall--

(1) include standards and guidance for manufacturers
seeking to develop and test new test strip technology;

(2) emphasize bringing new test strip technology intended
for testing human specimens in clinical settings to support on-
site clinical decision-making; and

(3) include guidance on available authorization pathways
for test strips described in paragraphs

(1) and

(2) .
SEC. 4.

The Secretary of Health and Human Services shall--

(1) conduct a study on the impact of the availability,
accessibility, and usage of drug checking supplies, including
test strips, on frequency of overdose, overdose deaths, and
engagement in substance use disorder treatment; and

(2) not later than 2 years after the date of enactment of
this Act, submit to Congress a report on the study conducted
under paragraph

(1) .
SEC. 5.

In this Act, the term ``test strip'' means a rapid response, single
use diagnostic that can be used to detect the adulteration of a drug
with, or the presence in a human specimen of, any substance that may
lead to increased morbidity or mortality, such as fentanyl, xylazine,
or another synthetic opioid or emerging substance.
<all>